Press Releases

Lease Includes Substantial Refurbishment and Approximately $6 Million Revenues Over 5 Years   BETHESDA, Md., October 17, 2017 – Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced it has leased an existing warehouse on the Company’s property in the UK to Commodity Centre Group, a commodity storage and distribution firm... Read More

BETHESDA, Md., September 20, 2017 – Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with institutional investors for a registered direct offering with gross proceeds of $1.75 million. In the transaction, the Company will sell approximately 8.75 million shares of common stock... Read More

DCVax®-L Phase III GBM Trial & DCVax-Direct Phase I/II Updates;  Overview Of A Broader Range Of DC Vax Public Data     BETHESDA, Md., September 1, 2017 – Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix L. Bosch, MBA, PhD and Chief Technical Officer of NW Bio presented an update on the Phase III Trial o... Read More

Debt Convertible at $0.25, $.50 and $1.00;  Secured By UK Property   BETHESDA, MD, June 22, 2017 – Northwest Biotherapeutics, Inc. (OTCQB: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, announced today that it has closed a convertible debt exchange and financing transaction with a non-affiliated investor and has completed the payoff of the... Read More

Updates to Include Both DCVax®-L Phase III Trial and DCVax®-Direct Phase I/II Trial BETHESDA, Md., June 5, 2017 – Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that this afternoon at 3:00 p.m. Central Time in the Industry Expert Theater in the Exhibit Hall at the ASCO Conference in the McCormick Place Convention Center in... Read More